Research progress on genome-guided precision oncology and development ideas of antitumor Chinese medicine.
10.19540/j.cnki.cjcmm.20221104.501
- Author:
Su-Fei HE
1
;
Miao WANG
2
Author Information
1. Ministry-Provincial Co-constructed Modern Chinese Medicine Cooperative Innovation Center,Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
2. School of Chinese Materia Medica,Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
- Publication Type:Journal Article
- Keywords:
genome-guided;
master protocol;
precision oncology;
synthetic lethality
- MeSH:
Humans;
Neoplasms/genetics*;
Medicine, Chinese Traditional;
Precision Medicine/methods*;
Medical Oncology;
Antineoplastic Agents/therapeutic use*
- From:
China Journal of Chinese Materia Medica
2023;48(6):1421-1430
- CountryChina
- Language:Chinese
-
Abstract:
Genome-guided oncology refers to a new treatment concept that transcends histological classification and pathological ty-ping and uses drugs according to the genetic characteristics of tumors. New drug development technology and clinical trial design based on this concept provide new ideas for the clinical application of precision oncology. The multi-component and multi-target characteristics of Chinese medicine provide rich resources for the development of tumor-targeting drugs from natural products, and the design of the master protocol trial aiming at the characteristics of precision oncology supports the rapid clinical screening of effective tumor-targeting drugs. The emergence of the synthetic lethality strategy breaks through the bottleneck that the drug can only target the oncogene but cannot do anything to the tumor suppressor gene with the loss-of-function mutation in the past. With the rapid development of high-throughput sequencing technology, the cost of sequencing is also decreasing. For the development of tumor-targeting drugs, how to keep up with the update speed of target information is a difficult problem of concern. Based on the integration of innovative ideas and me-thods of precision oncology, network pharmacology, and synthetic lethality strategy on synthetic lethal interaction network of antitumor Chinese medicine compatibility formula design, and the combination of improvement of innovative clinical trial methods, such as master protocol trial, basket trial, and umbrella trial, unique advantages of Chinese medicine are expected to be exerted beyond the antibody-based drugs and small molecule-based drugs and corresponding targeted drugs are potentially developed for clinical application.
